

26G-ISMS32 **Discovery of ASP3026, a Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor**

○ Kazuhiko IKUBO<sup>1</sup>, Yutaka KONDOH<sup>1</sup>, Itsuro SHIMADA<sup>1</sup>, Takahiro MATSUYA<sup>1</sup>, Kenichi MORI<sup>1</sup>, Yoko UENO<sup>1</sup>, Sadao KUROMITSU<sup>1</sup>, Minoru OKADA<sup>1</sup>

<sup>1</sup>Astellas Pharma Inc.

---

Anaplastic lymphoma kinase (ALK) is a promising therapeutic target for the treatment of cancers, including echinoderm microtubule-associated protein-like 4 (EML4)-ALK positive non-small cell lung cancer. We synthesized a series of 1,3,5-triazine derivatives and discovered ASP3026 as a potent and selective ALK inhibitor, which demonstrated dose-dependent antitumor activity in mice bearing NCI-H2228 tumor xenografts. ASP3026 also showed inhibitory activity against the L1196M gatekeeper mutant of ALK. Syntheses and structure-activity relationships of 1,3,5-triazine derivatives and computational modelings of ASP3026 will be presented.